Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Halabi, S.
Rini, B. I.
Stadler, W. M.
Small, E. J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy
    Heng, Daniel Y. C.
    Xie, Wanling
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Tan, Min-Han
    Knox, Jennifer
    Donskov, Frede
    Wood, Lori
    Kollmannsberger, Christian
    Rini, Brian I.
    Choueiri, Toni K.
    CANCER, 2011, 117 (12) : 2637 - 2642
  • [22] Primary hypertension to predict progression-free survival of target therapy in patients with metastatic renal cell carcinoma
    Chi, Zhi Hong
    Mao, Li Li
    Si, Lu
    Cui, Chuan Liang
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
    Levi, Francis
    Parganiha, Arti
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Giacchetti, Sylvie
    Garufi, Carlo
    Dispersyn, Garance
    Focan, C. N. J.
    Iacobelli, Stefano
    Bjarnason, Georg A.
    Moreau, Thierry
    Dugue, Pierre Antoine
    Waterhouse, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
    Giuliano, M.
    Giordano, A.
    Handy, B. C.
    Ueno, N.
    Andreopoulou, E.
    Alvarez, R. H.
    Valero, V.
    Hortobagyi, G. N.
    Reuben, J.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
  • [27] The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST).
    Stillman, Ipek Ozer
    Strand, Lauren N.
    Chang, Jane
    Mohamed, Ateesha F.
    Fahrbach, Kyle
    Freier, Katherine E. Tranbarger
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
    Teich, V
    Fernandes, R. A.
    VALUE IN HEALTH, 2017, 20 (09) : A863 - A863
  • [29] Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer
    Meropol, N. J.
    Cohen, S. J.
    Iannotti, N.
    Saidman, B. H.
    Sabbath, K. D.
    Miller, M. C.
    Doyle, G. V.
    Tissing, H.
    Terstappen, L. W. M. M.
    Punt, C. J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS)
    Stewart, D.
    Aljassim Alshareef, A.
    Robinson, A.
    Fung-Kee-Fung, M.
    Ong, M.
    Awan, A.
    Ocana, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1213 - S1213
12345